

v1: 12 September 2023

Research Article

Toxicological Evaluation of Aqueous Extracts of *Clematis hirsuta* and *Rhamnus prinoides*

Peer-approved: 12 September 2023

© The Author(s) 2023. This is an Open Access article under the CC BY 4.0 license.

Qeios, Vol. 5 (2023)
ISSN: 2632-3834

Caroline Wanjiku Kinuthia¹, James Mucunu Mbaria¹, Peter Mbaabu Mathiu²,
Loice Njeri Kamau³, Mitchel Otieno Okumu⁴

1. Department of Public Health, Pharmacology, and Toxicology, University of Nairobi, Kenya; 2. Department of Veterinary Anatomy and Physiology, University of Nairobi, Kenya; 3. Department of Biological and Agricultural Sciences, Kaimosi Friends University College, Kapsabet, Kenya; 4. University of Nairobi, Kenya

Clematis hirsuta leaves and *Rhamnus prinoides* roots have a long history of medicinal use in Nyeri County, Kenya. However, there is no evidence to back up their safety. The acute and subacute toxicity of *Clematis hirsuta* aqueous leaf and *Rhamnus prinoides* aqueous root extracts in Wistar rats was investigated in this study. Changes in body weight, feed and water consumption were used as toxicity indicators in the acute toxicity study, while changes in weight, biochemical and hematological parameters were used as toxicity indicators in the subacute toxicity study. The data from the acute toxicity study was summarized as mean±standard deviation and analyzed using the unpaired Student's t-test. The data from the subacute toxicity study was summarized as mean ±standard deviation and analyzed using Two Way ANOVA and Tukey's post hoc test. The significance level was set at $p \leq 0.05$. The extracts reduced feed and water consumption in rats but caused no physical signs of toxicity or death, nor did they have any significant effects on weight, biochemical, or hematological parameters when compared to controls. These findings indicate that oral administration of *Clematis hirsuta* aqueous leaf and *Rhamnus prinoides* aqueous root extracts to Wistar rats is generally nontoxic.

Corresponding author: Caroline Wanjiku Kinuthia,
carokin.ck@gmail.com

1. Background

Many developing countries rely on traditional herbal medicine to meet their primary healthcare needs [1][2][3][4]. Traditional herbal medicine has grown so rapidly that discussions about how to incorporate it into mainstream healthcare are ongoing [5][6][7][8]. Traditional medicine is popular among consumers due to its ease of use, low cost, proven efficacy, and perceived fewer side effects [9][10][11]. Secondary metabolites, which plants use for defense, protection against pests, diseases, insects, pathogenic organisms, and to attract pollinators, are credited with the

pharmacological efficacy of traditional herbal medicine [12][13][14]. Nonetheless, the safety of herbal medicine remains a hotly debated topic. Long-term studies, for example, have revealed the toxic properties of the Lamiaceae plant family monoterpenes [15]. Phytotoxic metabolites from the legume *Ascochyta* and *Phoma* [16], and child deaths in the Caribbean, Mexico, and Central America, due to *Thevetia peruviana*, *Chenopodium ambrosioides*, and *Argemone mexicana*, consumption have also been reported [17]. These studies demonstrate that, contrary to popular belief, not all traditional medicines are safe for consumption, emphasizing the importance of toxicological research.

Clematis hirsuta is a small climbing shrub that grows to a height of 4 m in Kenya, Uganda, Tanzania, and Saudi

Arabia [18][19]. It is a member of the Ranunculaceae family, with oppositely arranged compound leaves and panicles of white or yellow flowers [20]. In Asia and Africa (Ethiopia), it is used to treat inflammatory conditions and manage pain [19][20]. Abdel-Kader and colleagues isolated some compounds from the pet ether extract of *C. hirsuta*, including β -amyirin, stigmasterol glycoside, lupeol, (S)-(-)-5-hydroxymethyl-2(5H)-furanone, β -sitosterol, (S)-(+)-dihydro-5-(hydroxymethyl)-2(3H)-furanone, and oleanolic acid [21]. *C. hirsuta*'s ability to inhibit various disease-causing pathogens as well as its free radical scavenging properties have also been reported [20][22][23][24].

Rhamnus prinoides on the other hand is a dense evergreen shrub that can grow to 7.5 m in height. It is found in India, Ethiopia, Eritrea, South Africa, Cameroon, Congo, Angola, and Kenya and belongs to the Rhamnaceae family [25][26]. It has culinary and medicinal applications [26][27][28][29][30]. It is used as a bittering agent in the preparation of tella and tej, which are traditional fermented beverages from East Africa [27][28]. Medicinally, it is used to treat respiratory tract, skin, and gastrointestinal tract infections [26]. Quercetin, emodin, 4-hydroxy, 4-methyl pentanone, anthracene derivatives, geshoidin, and 4-ethylbenzoate are among the phytochemical compounds identified in the plant [26][31][32][33].

Leaves and roots of *Clematis hirsuta* and *Rhamnus prinoides* respectively are used to treat type 2 diabetes in Nyeri County, Kenya [34]. However, no consideration has been given to the safety of these medicinal plants. The current study sought to determine the safety of *Clematis hirsuta* leaves and *Rhamnus prinoides* roots in Wistar rats by measuring changes in weight, biochemical, and hematological parameters.

2. Methods

2.1. Ethical considerations

The University of Nairobi's Biosafety, Animal Use and Ethics Committee was consulted for ethical approval. REF FVM BAUEC/2022/392.

2.2. Materials

Leaves of *Clematis hirsuta* and roots of *Rhamnus prinoides* were sourced from Nyeri County. The equipment used in this experiment included an electric mill (Tencan, China), analytical balance (Mettler, USA), Muslin cloth (Sciencequip, Kenya), Centrifuge (Sigma

Aldrich, USA), freeze drier (Bioevopeak, USA), Wistar rats (Animal holding unit, University of Nairobi), polypropylene cages (Industrial area, Nairobi), and Hematology and Biochemistry kits (Mindray, China).

2.3. Medicinal plant collection and identification

Herbalists from Nyeri County assisted in collecting leaves and roots of *C. hirsuta* and *R. prinoides* respectively. Plant specimens were collected and stored in a plant press until they could be identified botanically. After that, the specimens were identified at the University of Nairobi Herbarium, where voucher specimens were also deposited.

2.4. Preparation of medicinal plant extracts

Plant materials were carefully sorted and washed under running tap water. After one week of shade drying, the plant material was pulverized using an electric mill, weighed and mixed with distilled water in a ratio of 1:10. Hot water extraction was performed to mimic the traditional method of decoction preparation. The mixture was strained using a muslin cloth, filtered, and centrifuged at 3000 rpm for 5 minutes, and the supernatant was collected. The supernatant was freeze-dried (Mondulyo-UK) and stored at -20°C pending toxicological testing.

2.5. Experimental animals

The animal holding unit of the Department of Veterinary Anatomy and Physiology, Faculty of Veterinary Medicine, University of Nairobi provided fifty-six 8-10-week-old female Wistar rats. The rats were randomly selected, weighed (180-200 grams), and transferred to polypropylene cages. They were then marked to permit identification and a period of five days was used to acclimatize the rats to the laboratory conditions (20-25°C and a 12-hour light and dark cycle). Water and food (Unga rat pellets) were provided *ad libitum*.

2.6. Acute toxicity

The acute toxicity of *C. hirsuta* aqueous leaf and *R. prinoides* aqueous root extracts in twenty-one female Wistar rats was determined using the Limit Test Dose of the Up and Down Procedure Method [35]. Each group contained five rats, and the maximum dose of each extract was 2000 mg/kg. Only distilled water was given to the rats in the control group. Over a two-week period, the control and treatment rats' feed and water consumption, as well as their mean body weight gain, were measured.

2.7. Subacute toxicity

The sub-acute toxicity of *C. hirsuta* aqueous leaf and *R. prinoides* aqueous root extracts was determined using the Up and Down Procedure on 35 female Wistar rats [36]. Each group had five animals, with extract doses of 25 mg/kg, 75 mg/kg, and 225 mg/kg. The control group only received distilled water. The weight, hematological, and biochemical parameters of the control and treatment animals were measured over a four-week period [36].

2.8. Statistical analysis

In the acute toxicity protocol, the student's test was used to compare differences in the mean body weight gain, and the mean feed and water consumption of control and treatment group rats. Differences in

hematological and biochemical changes between treatment and control group rats were assessed using two-way ANOVA and Tukey's post hoc test in the sub-acute toxicity protocol. The level of significance was set at $p \leq 0.05$. GraphPad Prism (9.0) and GenStat (15th edition) were used as statistical tools.

3. Results

3.1. Acute toxicity

3.1.1. Mean feed consumption

Figures 1 A and B compare the mean feed consumption in rats given 2000 mg/kg of *Clematis hirsuta* aqueous leaf extract or *Rhamnus prinoides* aqueous root extract to the mean feed consumption in rats given only distilled water.




Figure 1. Feed consumption in *C. hirsuta* aqueous leaf extract (A) or *R. prinoides* aqueous root extract (B) treated rats relative to feed consumption in control group rats after 14 days.

The mean feed consumption of rats in the *C. hirsuta* treatment group was significantly lower than that of rats in the control group ($p=0.0222$). **Figure 1A.** The mean feed consumption of rats in the *R. prinoides* treatment group was significantly lower than that of rats in the control group ($p=0.0014$). **Figure 1B.**

3.1.2. Mean water consumption

Figures 2 A and B compare the mean water consumption in rats given 2000 mg/kg of *Clematis hirsuta* aqueous leaf or *Rhamnus prinoides* aqueous root extracts to the mean water consumption in rats given distilled water only.




Figure 2. Water consumption in *C. hirsuta* aqueous leaf extract (A) or *R. prinoides* aqueous root extract (B) treated rats relative to water consumption in control group rats after 14 days

The mean water consumption of rats in the *C. hirsuta* treatment group did not differ significantly from that of rats in the control group ($p=0.1187$). **Figure 2A.** The mean water consumption in the *R. prinoides* treatment group was significantly lower than that in the control group ($p=0.0010$). **Figure 2B.**

3.1.3. Mean body weight

Figures 3 A and B compare the mean body weight gain in rats given 2000 mg/kg of *Clematis hirsuta* aqueous leaf or *Rhamnus prinoides* aqueous root extracts to the mean body weight gain in rats given only distilled water.




Figure 3. Mean body weight gain in *C. hirsuta* aqueous leaf extract (A) or *R. prinoides* aqueous root extract (B) treated rats relative to the mean body weight in control group rats after 14 days

There was no statistically significant difference in mean body weight gain between *C. hirsuta* treatment group rats and control rats ($p=0.2181$). **Figure 3A.** However, the mean body weight of rats given 2000 mg/kg of *R. prinoides* aqueous root extract was significantly higher than the mean body weight of rats given only distilled water ($p=0.0351$). **Figure 3B.**

3.1.4. Physical examination of rats for signs of toxicity

There were no changes in the colour of the skin, hair, eyes, mucous membranes, respiration or motor activity. No convulsion, tremors, salivation, diarrhoea, lethargy, sleep or mortality was observed during the first 24 hours and after 14 days of treatment with *Clematis hirsuta* aqueous leaf extract or *Rhamnus prinoides* aqueous root extract. The results show that the LD₅₀ for both extracts was >2000 mg/kg.

3.2. Subacute toxicity

During the experimental period for the subacute toxicity study (28 days), there were no signs of toxicity or mortality in treated rats. The results showed that the extracts' LD₅₀ was > 225 mg/kg. Furthermore, the weight gain in extract-treated rats was not significantly different ($p>0.05$) from the weight gain in untreated (control) rats in the second week of treatment. **Figure 4A.** Rats given 75 mg/kg and 225 mg/kg *C. hirsuta* aqueous leaf extract gained significantly more weight than untreated (control) rats in the third week of treatment ($p=0.0011$ and $p=0.0011$ for 75 mg/kg and 225 mg/kg respectively). **Figure 4A.** *C. hirsuta* aqueous leaf extract-treated rats gained significantly more weight than untreated (control) rats in the fourth week of treatment ($p=0.0003$, $p<0.0001$, and $p=0.0004$ for 25mg/kg, 75mg/kg, and 225mg/kg respectively). **Figure 4A.**




Figure 4. Percentage of weight gain in experimental animals after 28 days of different doses of *C. hirsuta* aqueous leaf extract (A) and *R. prinoides* aqueous root extract (B)

Rats given the highest dose of *R. prinoides* aqueous root extract gained significantly more weight than untreated (control) rats in the first and second weeks of treatment. **Figure 4B.** (Week 1, $p=0.01$, and Week 2, $p<0.0001$). Rats given 75mg/kg and 225 mg/kg of *R. prinoides* aqueous root extract gained significantly more weight than untreated (control) rats in the third week of treatment ($p<0.0001$, and $p<0.0001$ for 75mg/kg and 225 mg/kg respectively). **Figure 4B.** Rats given 25 mg/kg, 75 mg/kg, and 225 mg/kg doses of *R. prinoides* aqueous root extract gained significantly more weight than untreated (control) rats in the fourth week of treatment. **Figure 4B.** ($p=0.0490$, $p<0.0001$, and $p<0.0001$ for 25mg/kg, 75mg/kg, and 225mg/kg respectively)

3.3. Hematological values

Table 1 shows the effect of different doses of *C. hirsuta* aqueous leaf and *R. prinoides* aqueous root extracts on hematological parameters in rats after 28 days. The hematological parameters examined in this study included white blood cells, mean corpuscular hemoglobin concentration, eosinophils, neutrophils, mean corpuscular hemoglobin, hematocrit, lymphocytes, monocytes, mean corpuscular volume, basophils, red blood cells, hemoglobin, and platelets.

Hematological values	Experimental groups (n=5)						
	Control	25 mg/kg CH	75 mg/kg CH	225 mg/kg CH	25 mg/kg RP	75 mg/kg RP	225 mg/kg RP
WBC (10 ³ /μL)	4.81 ^a ±0.93	7.74 ^a ±1.91	3.49 ^a ±0.41	6.21 ^a ±0.81	8.32 ^a ±1.47	7.19 ^a ±0.45	7.69 ^a ±1.77
NEU (10 ³ /μL)	2.52 ^a ±1.16	2.65 ^a ±0.71	1.93 ^a ±0.29	1.55 ^a ±0.15	2.54 ^a ±0.36	1.65 ^a ±0.48	3.33 ^a ±0.68
LYM (10 ³ /μL)	2.60 ^a ±0.37	7.27 ^b ±0.90	4.44 ^a ±0.49	4.48 ^a ±0.50	7.38 ^a ±1.66	6.49 ^a ±1.58	21.96 ^a ±9.80
MON (10 ³ /μL)	0.96 ^a ±0.84	0.64 ^a ±0.21	0.43 ^a ±0.15	0.31 ^b ±0.05	0.86 ^a ±0.17	0.52 ^a ±0.12	0.15 ^b ±2.72
EO (10 ³ /μL)	0.45 ^a ±0.41	0.08 ^a ±0.01	0.02 ^a ±0.00	0.02 ^a ±0.01	0.02 ^a ±0.01	0.08 ^a ±0.06	0.35 ^a ±0.11
BAS (10 ³ /μL)	0.18 ^{ab} ±0.11	0.32 ^b ±0.06	0.02 ^a ±0.01	0.06 ^{ab} ±0.04	0.07 ^a ±0.02	0.04 ^a ±0.01	0.37 ^a ±0.12
RBC (10 ⁶ /μL)	5.12 ^a ±0.34	4.96 ^a ±0.82	4.37 ^a ±0.72	6.03 ^a ±0.55	5.09 ^a ±0.55	4.48 ^a ±0.79	5.34 ^a ±0.69
HGB (g/dL)	13.24 ^a ±0.51	12.00 ^a ±1.80	10.80 ^a ±1.78	13.74 ^a ±0.21	12.38 ^a ±1.18	12.06 ^a ±1.32	12.50 ^a ±1.31
MCH (pg)	26.16 ^a ±1.63	24.54 ^a ±2.10	24.86 ^a ±2.11	23.68 ^a ±2.49	24.70 ^a ±2.02	29.56 ^a ±3.87	24.00 ^a ±2.21
HCT (%)	40.36 ^a ±2.30	36.16 ^a ±5.85	33.78 ^a ±6.41	41.68 ^a ±1.37	37.50 ^a ±4.40	34.70 ^a ±6.67	38.62 ^a ±4.78
MCV (fL)	80.00 ^a ±6.77	73.96 ^a ±8.87	76.38 ^a ±8.85	72.52 ^a ±9.41	74.72 ^a ±8.52	76.36 ^a ±8.93	73.66 ^a ±8.21
MCHC (g/dL)	32.9 ^a ±0.80	33.66 ^a ±1.14	33.06 ^a ±1.51	33.08 ^a ±0.82	33.50 ^a ±1.12	41.20 ^a ±8.59	32.82 ^a ±1.20
PLT (10 ³ /μL)	171.20 ^{ab} ±65.20	305.00 ^{ab} ±46.56	107.80 ^a ±52.90	410.60 ^b ±107.20	301.00 ^a ±88.65	239.00 ^a ±88.65	274.80 ^a ±76.09

Table 1. Toxicological effect of *Clematis hirsuta* aqueous leaf and *Rhamnus prinoides* root extract on various hematological parameters in rats after 28 days

Values are shown in terms of (mean ± SEM, n = 5). Means where the superscripts are different across the rows are significantly different at $p < 0.05$. mg/kg; milligrams per kilogram, CH; *Clematis hirsuta*, RP: *Rhamnus prinoides*, WBC; white blood cells, HCT; hematocrit, MON; monocytes, NEU; neutrophils, LYM; lymphocytes, EO; eosinophils, MCV; mean corpuscular volume, BAS; basophils, PLT; platelets, RBC; red blood cells, HGB; hemoglobin, MCH; mean corpuscular hemoglobin, MCHC; mean corpuscular hemoglobin concentration; μL; microliters, g/dL; grams per deciliter, pg; picograms, %; percentage, fL; ounces.

There was no statistical difference ($p > 0.05$) between *C. hirsuta* leaf or *R. prinoides* root-treated rats and untreated (control) rats in platelets, white blood cells, eosinophils, red blood cells, neutrophils, basophils, hemoglobin, mean corpuscular hemoglobin,

hematocrit, mean corpuscular volume, and mean corpuscular hemoglobin concentration. (Table 1). The mean lymphocyte values in rats treated with a 25 mg/kg dose of *C. hirsuta* aqueous leaf extract were significantly higher ($p < 0.05$) than in untreated (control) rats. (Table 1). Rats given 225 mg/kg doses of *C. hirsuta* aqueous leaf extract or *R. prinoides* aqueous root extract had significantly lower ($p < 0.05$) mean monocyte levels than untreated (control) rats (Table 1).

3.4. Biochemical values

Table 2 shows the effect of different doses of *C. hirsuta* aqueous leaf and *R. prinoides* aqueous root extracts on biochemical parameters in rats after 28 days. Among the biochemical parameters studied were bilirubin, urea, albumin, total protein, alanine aminotransferase, sodium, alkaline phosphatase, creatinine, aspartate aminotransferase, chloride, and potassium.

Biochemical values	Experimental groups (n=5)						
	Control	25 mg/kg CH	75 mg/kg CH	225 mg/kg CH	25 mg/kg RP	75 mg/kg RP	225 mg/kg RP
Albumin (10 ³ /μL)	43.91 ^a ±0.46	41.18 ^a ±0.93	43.42 ^a ±1.26	43.02 ^a ±1.05	41.57 ^a ±0.46	43.78 ^a ±0.86	42.27 ^a ±1.52
ALP (U/L)	191.20 ^b ±5.35	137.60 ^a ±9.66	140.70 ^a ±9.31	200.20 ^a ±10.17	161.50 ^a ±11.27	186.30 ^a ±28.26	151.60 ^a ±4.52
ALT (U/L)	180.50 ^a ±10.85	167.90 ^a ±11.66	170.69 ^a ±6.93	166.80 ^a ±16.95	174.70 ^a ±10.70	180.30 ^a ±15.60	177.70 ^a ±34.95
AST (U/L)	446.10 ^a ±58.20	428.10 ^a ±10.74	433.40 ^a ±13.48	435.70 ^a ±51.20	442.70 ^a ±12.81	438.50 ^a ±10.37	471.80 ^a ±80.98
Bilirubin (μmol/L)	0.84 ^a ±0.12	0.92 ^a ±0.04	0.96 ^a ±0.12	0.88 ^a ±0.09	1.00 ^a ±0.10	0.86 ^a ±0.13	0.84 ^a ±0.08
Chloride (mmol/L)	113.70 ^a ±1.64	118.29 ^a ±2.47	114.50 ^a ±1.33	115.99 ^a ±0.63	116.90 ^{ab} ±0.50	118.30 ^b ±0.57	114.70 ^{ab} ±0.13
Creatinine (μmol/L)	32.00 ^b ±2.98	24.00 ^a ±1.00	26.60 ^{ab} ±1.29	28.00 ^{ab} ±1.23	31.00 ^a ±1.92	30.00 ^a ±0.89	27.00 ^a ±0.51
K (mmol/L)	10.65 ^b ±0.33	6.56 ^a ±0.21	7.25 ^a ±0.10	6.76 ^a ±0.44	8.07 ^a ±0.51	10.33 ^a ±0.98	9.58 ^a ±0.63
Na (mmol/L)	137.30 ^a ±1.59	142.00 ^b ±0.94	140.60 ^{ab} ±0.79	142.50 ^b ±0.46	144.60 ^b ±0.34	140.80 ^{ab} ±0.44	144.80 ^{ab} ±1.21
Total protein (g/L)	81.30 ^b ±2.41	72.80 ^a ±1.48	80.94 ^b ±1.58	80.18 ^b ±1.59	76.00 ^a ±0.32	80.62 ^a ±0.86	74.28 ^a ±2.23
Urea (mmol/L)	12.45 ^b ±0.85	9.55 ^a ±0.23	10.73 ^{ab} ±0.31	11.00 ^b ±0.45	9.08 ^a ±0.34	11.28 ^{bc} ±0.10	9.61 ^{abc} ±0.31

Table 2. Toxicological effect of *Clematis hirsuta* aqueous leaf and *Rhamnus prinoides* root extract on various biochemical parameters in rats after 28 days.

Values are shown as (mean ± SEM, n = 5). Means where the superscripts are different across the rows are significantly different at $p < 0.05$. mg/kg; milligrams per kilogram, CH; *Clematis hirsuta*, RP: *Rhamnus prinoides*, ALT; alanine aminotransferase, AST; aspartate aminotransferase, K; potassium, ALP; alkaline phosphatase, Na; Sodium

Treatment of rats with 25mg/kg, 75 mg/kg, or 225 mg/kg doses of *C. hirsuta* aqueous leaf extract or 25mg/kg, 75 mg/kg, or 225 mg/kg doses of *R. prinoides* aqueous root extract was associated with a non-statistically significant change ($p > 0.05$) in the mean albumin, bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) values relative to untreated (control) rats. (Table 2). The mean alkaline phosphatase (ALP) and potassium levels in rats treated with *C. hirsuta* aqueous leaf extract or *R. prinoides* aqueous root extract were significantly lower ($p < 0.05$) than in untreated (control) rats (Table 2). The mean creatinine levels in rats treated with *R. prinoides*

aqueous root extract were significantly lower ($p < 0.05$) than in untreated (control) rats (Table 2).

The mean alkaline phosphatase (ALP) and potassium levels in rats treated with *C. hirsuta* aqueous leaf extract or *R. prinoides* aqueous root extract were significantly lower ($p < 0.05$) than in untreated (control) rats (Table 2). The mean chloride value was significantly higher ($p < 0.05$) in rats treated with 75 mg/kg *R. prinoides* aqueous root extract than in untreated (control) rats (Table 2). The mean creatinine levels in rats treated with 25 mg/kg, 75 mg/kg, or 225 mg/kg *R. prinoides* aqueous root extract or 25 mg/kg *C. hirsuta* aqueous leaf extract were significantly lower ($p < 0.05$) than in untreated (control) rats (Table 2).

The sodium levels were significantly higher ($p < 0.05$) in rats given 25 mg/kg and 225 mg/kg *C. hirsuta* aqueous leaf extract or 25 mg/kg *R. prinoides* aqueous root extract than in untreated (control) rats (Table 2). The mean total protein values in rats treated with 25 mg/kg, 75 mg/kg, or 225 mg/kg *R. prinoides* aqueous root extract or *C. hirsuta* aqueous leaf extract were

significantly lower ($p < 0.05$) than in untreated (control) rats (Table 2). The mean urea levels in rats treated with 25 mg/kg of *C. hirsuta* aqueous leaf extract or 25 mg/kg of *R. prinoides* aqueous root extract were significantly lower ($p < 0.05$) than in rats that were not treated (control) (Table 2).

4. Discussion

When evaluating the safety of medicinal plants, it is critical to determine the nature, significance, and level of exposure at which untoward effects occur [37][38]. The current study investigated the safety of *Clematis hirsuta* aqueous leaf and *Rhamnus prinoides* aqueous root extracts in rats.

Toxicology data on *C. hirsuta* presented in the current study was a mixed bag. For instance, in the acute toxicity study, rats given 2000 mg/kg of *C. hirsuta* aqueous leaf extract exhibited weight gain relative to control group rats with no physical signs of toxicity after 24 hours or 14 days. Ironically, *C. hirsuta*-treated rats had lower feed and water consumption rates than control group rats. For toxic substances, the expectation is that the ability of the rats to feed and consume water will be compromised. If this is the case, it is not expected that the rats will have a higher weight gain than the control group rats as was observed in this study. More studies are required to understand this discrepancy. In the subacute toxicity protocol, there were no significant changes in weight gain, hematological, or biochemical parameters between *Clematis hirsuta*-treated rats and controls. Because this may be the first study on the toxicology of *Clematis hirsuta*, it may be important to compare our findings with toxicological data from other medicinal plants within the genus *Clematis*. The genus *Clematis*, for example, generally contains protoanemonin, a compound which irritates the skin and mucous membranes [39][40]. A 34-year-old man who used *Clematis chinensis* for wrist pain developed hypo- and hyperpigmentation, as well as pruritic erythema [41]. According to another report, *Clematis chinensis* can cause bullae, abdominal cramping, palpitations, inflammation, hypersalivation, bloody diarrhoea, blistering, inflamed eyes, vomiting, and weakness [42]. Two milligrams of Clematine (an alkaloid isolated from *Clematis flammula*) caused frequent urination, general tremors, altered respiration, palpitations, convulsions, coma, and death in guinea pigs [43]. The poisonous nature of *Clematis glycinoides* limits its use in veterinary medicine [44]. The aerial parts of *Clematis mandshurica* and its essential oil had LD₅₀ values of 51.85 mg/kg and

3.28 ml/kg respectively in mice [45]. Convulsions, confusion, and dizziness have been reported following the use of *Clematis virginiana* [46]. Beggars in ancient Rome applied *Clematis* spp. juice on their hands to cause blisters in order to gain more sympathy from people [46].

The administration of *R. prinoides* aqueous root extract to Wistar rats did not result in any physical signs of toxicity during the first 24 hours or after 14 days and was associated with significant weight gain relative to the control. However, the feed and water consumption in *R. prinoides*-treated rats were lower than in the control group rats. Furthermore, there were no significant differences in weight gain, hematological, or biochemical parameters between *R. prinoides* aqueous root extract-treated rats and controls. There have been few studies on the safety of *R. prinoides* [47][48][49]. Kamanja found that *R. prinoides* aqueous root, methanol-water, and chloroform extracts were toxic to *Artemia salina*, with LC₅₀ values of 6921.05 g/mL, 214.33 g/mL, and 133.33 g/mL, respectively [47]. In human oral epidermoid cancer cell lines, Koch and colleagues found an IC₅₀ of more than 20 µg/mL for *R. prinoides* root bark chloroform extract [48]. Another study found that *R. prinoides* aqueous leaf extract caused mortality ranging from 11.67% to 88.33% in the mendi termite (*Macrotermes subhyalinus*) when treated for 24 to 72 hours [49].

This study did not evaluate the effects of *C. hirsuta* aqueous leaf and *R. prinoides* aqueous root extracts on major organs in Wistar rats. Future work should examine the extracts' pathological effects on major organs in rats, as well as their phytochemical composition and pharmacological properties.

5. Conclusions

The findings reveal that *C. hirsuta* aqueous leaf extracts and *R. prinoides* aqueous root extracts are generally safe when orally administered in Wistar rats.

Data availability

The data used to support the findings of this study are available from the corresponding author upon request

Conflicts of interest

The author(s) declare that there is no conflict of interest regarding the publication of this paper

Funding Statement

This work did not receive any funding

Acknowledgments

The authors would like to acknowledge the herbalist who assisted in the collection of the plant as well as Mr. Daniel Kwoba, a senior laboratory technician at the Department of Veterinary Anatomy and Physiology, University of Nairobi.

References

1. [△]S. Joos, K. Glassen, and B. Musselmann, "Herbal medicine in primary healthcare in Germany: the Patient's perspective," *Evidence-Based Complementary and Alternative Medicine*, vol. 2012, 2012.
2. [△]D. S. Nsagha, C. W. Ayima, T. Nana-Njamen, and J. C. N. Assob, "The role of traditional, complementary/alternative medicine in primary healthcare, adjunct to universal health coverage in Cameroon: a review of the literature," *American Journal of Epidemiology*, vol. 8, no. 1, pp. 37–47, 2020.
3. [△]A. Shirwaikar, R. Govindarajan, and A. K. S. Rawat, "Integrating complementary and alternative medicine with primary health care," *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Hindawi, 2013.
4. [△]U. Payyappallimana, "Role of traditional medicine in primary health care: an overview of perspectives and challenging," 2010.
5. [△]E. Asante and R. Avoronyo, "Enhancing health care system in Ghana through the integration of traditional medicines," *Journal of Social Research*, vol. 4, no. 2, 2013.
6. [△]A. Kwame, "Integrating Traditional Medicine and Healing into the Ghanaian Mainstream Health System: Voices from Within," *Qualitative Health Research*, vol. 31, no. 10, pp. 1847–1860, 2021.
7. [△]J. A. Astin, A. Marie, K. R. Pelletier, E. Hansen, and W. L. Haskell, "A review of the incorporation of complementary and alternative medicine by mainstream physicians," *Archives of internal medicine*, vol. 158, no. 21, pp. 2303–2310, 1998.
8. [△]S. J. Oliver, "The role of traditional medicine practice in primary health care within Aboriginal Australia: a review of the literature," *Journal of ethnobiology and ethnomedicine*, vol. 9, no. 1, pp. 1–8, 2013.
9. [△]M. S. Wani, S. R. Parakh, M. H. Dehghan, et al., "Herbal medicine and its standardization," *Pharmaceutical Reviews*, vol. 5, no. 6, 2007.
10. [△]D. Sun, S. Li, Y. Liu, et al., "Differences in the origin of philosophy between Chinese medicine and western medicine: exploration of the holistic advantages of Chinese medicine," *Chinese journal of integrative medicine*, vol. 19, no. 9, pp. 706–711, 2013.
11. [△]F. Carmona and A. M. S. Pereira, "Herbal medicines: old and new concepts, truths and misunderstandings," *Revista Brasileira de Farmacognosia*, vol. 23, no. 2, pp. 379–385, 2013.
12. [△]O. Ifeoma and S. Oluwakanyinsola, "Screening of herbal medicines for potential toxicities," *New insights into toxicity and drug testing*, vol. 244, pp. 63–88, 2013.
13. [△]G. Saxena, A. Mittal, and A. W. Siddiqui, "Evaluation of preliminary phytochemical screening, acute toxicity and antioxidant profile of *Ocimum kilimandscharicum*," *Journal of Drug Delivery and Therapeutics*, vol. 9, no. 2, pp. 372–375, 2019.
14. [△]B. D'Abrosca, M. DellaGreca, A. Fiorentino, P. Monaco, and A. Zarrelli, "Low molecular weight phenols from the bioactive aqueous fraction of *Cestrum parqui*," *Journal of Agricultural and Food Chemistry*, vol. 52, no. 13, pp. 4101–4108, 2004.
15. [△]K. A. Wojtunik-Kulesza, "Toxicity of Selected Monoterpene and Essential Oils Rich in These Compounds," *Molecules*, vol. 27, no. 5, p. 1716, Mar. 2022.
16. [△]W. Kim and W. Chen, "Phytotoxic Metabolites Produced by Legume-Associated *Ascochyta* and Its Related Genera in the *Dothideomycetes*," *Toxins*, vol. 11, no. 11, Oct. 2019.
17. [△]A. J. Alonso-Castro, F. Domínguez, A. J. Ruiz-Padilla, et al., "Medicinal Plants from North and Central America and the Caribbean Considered Toxic for Humans: The Other Side of the Coin," *Evidence-based complementary and alternative medicine: eCAM*, vol. 2017, 2017.
18. [△]"*Clematis hirsuta* Perr. & Guill. [family RANUNCULACEAE] on JSTOR." [Online]. Available: <https://plants.jstor.org/stable/10.5555/al.ap.flora.fta000009>. [Accessed: 29-May-2022].
19. [△]A. M. Al-Taweel, K. S. El-Deeb, M. S. Abdel-Kader, and J. S. Mossa, "GC/MS Analysis of the Fatty Acids of Three *Clematis* species Growing in Saudi Arabia and their Anti-inflammatory activity," *Saudi Pharmaceutical Journal*, vol. 15, no. 3/4, p. 224, 2007.
20. [△]A. M. Al-Taweel, K. S. El-Deeb, M. S. Abdel-Kader, and J. S. Mossa, "Antibacterial potential of the 80 % methanol and chloroform extracts of *Clematis hirsuta*," vol. 11, no. 16, pp. 204–208, 2017.
21. [△]M. S. Abdel-Kader, A. M. Al-Taweel, and K. S. El-Deeb, "Bioactivity guided phytochemical study of *Clematis hirsuta* growing in Saudi Arabia," *Natural Product Sciences*, vol. 14, no. 1, pp. 56–61, 2008.

22. [△]Z. Abdisa and F. Kenea, "Phytochemical screening, antibacterial and antioxidant activity studies on the crude root extract of *Clematis hirsuta*," *Cogent Chemistry*, vol. 6, no. 1, p. 1862389, 2020.
23. [△]P. Cos, N. Hermans, T. De Bruyne, et al., "Further evaluation of Rwandan medicinal plant extracts for their antimicrobial and antiviral activities," *Journal of Ethnopharmacology*, vol. 79, no. 2, pp. 155–163, Feb. 2002.
24. [△]M. Azemeraw, "Studies on anti-oxidative and antibacterial activities of the leaves extract of *clematis hirsuta* (Nech yeazo hareg)." 2020.
25. [△]"*Rhamnus prinoides* - Useful Tropical Plants." [Online]. Available: <https://tropical.theferns.info/viewtropical.php?id=Rhamnus+prinoides>. [Accessed: 29-May-2022].
26. [△]_b [△]_c [△]_d M. Campbell, W. Zhao, R. Fathi, M. Mihreteab, and E. S. Gilbert, "Rhamnus prinoides (gesho): A source of diverse anti-biofilm activity," *Journal of Ethnopharmacology*, vol. 241, p. 111955, 2019.
27. [△]_b G. Mulaw and A. Tesfaye, "Technology and microbiology of traditionally fermented food and beverage products of Ethiopia: a review," *African Journal of Microbiology Research*, vol. 11, no. 21, pp. 825–844, 2017.
28. [△]_b M. Lee, M. Regu, and S. Seleshe, "Uniqueness of Ethiopian traditional alcoholic beverage of plant origin, tella," *Journal of Ethnic Foods*, vol. 2, no. 3, pp. 110–114, 2015.
29. [△]J. W. Kiringe, "A survey of traditional health remedies used by the Maasai of Southern Kaijiado District, Kenya," 2006.
30. [△]T. Teklehaymanot and M. Giday, "Ethnobotanical study of medicinal plants used by people in Zegie Peninsula, Northwestern Ethiopia," *Journal of ethnobiology and Ethnomedicine*, vol. 3, no. 1, pp. 1–11, 2007.
31. [△]B. M. Abegaz and T. Kebede, "Geshoidin: A bitter principle of *Rhamnus prinoides* and other constituents of the leaves," *Bulletin of the Chemical Society of Ethiopia*, vol. 9, no. 2, 1995.
32. [△]T. G. Amabye, "Evaluation of phytochemical, chemical composition, antioxidant and antimicrobial screening parameters of *Rhamnus prinoides* (Gesho) available in the market of Mekelle, Tigray, Ethiopia," *Nat. Prod. Chem. Res.*, vol. 3, no. 6, 2015.
33. [△]M. M. Nindi, B. V Kgarabe, J. Wolfender, and B. M. Abegaz, "Electrospray liquid chromatography–mass spectrometry of the leaf extract of *Rhamnus prinoides*," *Phytochemical Analysis*, vol. 10, no. 2, pp. 69–75, 1999.
34. [△]L. N. Kamau, M. P. Mbaabu, J. M. Mbaria, G. P. Karuri, and S. G. Kiama, "Knowledge and demand for medicinal plants used in the treatment and management of diabetes in Nyeri County, Kenya," *Journal of Ethnopharmacology*, pp. 1–12, 2016.
35. [△]O. Guideline, F. O. R. Testing, and O. F. Chemicals, "Acute Oral Toxicity – Acute Toxic Class Method," no. December, pp. 1–14, 2001.
36. [△]_b O. Guidelines, "Repeated dose 28-day oral toxicity study in rodents," *Oecd Guidelines for the Testing of Chemicals*, no. October, pp. 1–13, 2008.
37. [△]M. B. Ibrahim, A. A. Sowemimo, M. O. Sofidiya, et al., "Sub-acute and chronic toxicity profiles of *Markhamia tomentosa* ethanolic leaf extract in rats," *Journal of ethnopharmacology*, vol. 193, pp. 68–75, 2016.
38. [△]C. J. Ugwah-Oguejiofor, C. O. Okoli, M. O. Ugwah, et al., "Acute and sub-acute toxicity of aqueous extract of aerial parts of *Caralluma dazielii* NE Brown in mice and rats," *Heliyon*, vol. 5, no. 1, p. e01179, 2019.
39. [△]D. Frohne, H. J. Pfander, and H. J. Pfänder, *Poisonous plants: a handbook for doctors, pharmacists, toxicologists, biologists and veterinarians*. Timber Press (OR), 2005.
40. [△]G. L. Tilford, *Edible and medicinal plants of the West*. Mountain Press Publishing, 1997.
41. [△]C. Tan, W.-Y. Zhu, and Z.-S. Min, "Co-existence of contact leukoderma and pigmented contact dermatitis attributed to *Clematis chinensis* Osbeck," *Contact dermatitis*, vol. 58, no. 3, pp. 177–178, 2008.
42. [△]N. J. Turner and A. F. Szczawinski, *Common poisonous plants and mushrooms of North America*. Timber Press, 1991.
43. [△]J. P. Remington, H. C. Wood, S. P. Sadtler, et al., *The dispensatory of the United States of America*. Lippincott Philadelphia, PA, 1918.
44. [△]E. V Lassak and T. McCarthy, *Australian medicinal plants*. Methuen Australia, 1983.
45. [△]F. J. Sun and X. J. Li, "Study on acute toxicity of *Clematis mandshurica* and its essential oil," *Research and Practice of Chinese Medicines*, vol. 19, no. 1, pp. 41–42, 2005.
46. [△]_b R. Chawla, S. Kumar, and A. Sharma, "The genus *Clematis* (Ranunculaceae): Chemical and pharmacological perspectives," *Journal of Ethnopharmacology*, vol. 143, no. 1, pp. 116–150, 2012.
47. [△]_b I. T. Kamanja, "Study of Antimicrobial, Phytochemical and Toxicological Properties of Selected Plants Used in the Management of Sexually Transmitted Infections in Samburu County, Kenya," p. 217, 2014.
48. [△]_b A. Koch, P. Tamez, J. Pezzuto, and D. Soejarto, "Evaluation of plants used for antimalarial treatment by the Maasai of Kenya," *Journal of Ethnopharmacology*, vol. 101, no. 1–3, pp. 95–99, 2005.

49. ^{a, b}W. B. Kassie, "Evaluation of Selected Botanical Extracts against Mendi Termite *Macrotermes subhyalinus*

(Isoptera: Termitidae), under Laboratory Condition," *Current Research in Agricultural Sciences*, vol. 6, no. 2, p. 135–140, 2019.

Declarations

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.